Anixa Biosciences, Inc. - ANIX STOCK NEWS

Anixa Biosciences (NASDAQ: ANIX) announced the issuance of its first U.S. patent for an innovative ovarian cancer vaccine technology, developed in collaboration with Cleveland Clinic. The patent, titled "Ovarian Cancer Vaccines," focuses on a protein expressed in pre-menopausal women's ovaries, which is also found in ovarian cancer cells. By training the immune system to target this protein, the vaccine aims to prevent ovarian cancer's onset. The technology is already patented in Europe, and further development will be supported by the National Cancer Institute's PREVENT program.

On May 26, 2021, Anixa Biosciences (NASDAQ: ANIX) announced its ovarian cancer vaccine technology is receiving support from the National Cancer Institute (NCI). This collaboration is facilitated through the NCI-PREVENT program, which aims to develop cancer prevention interventions. Key milestones include immunogenicity testing, vaccine production development, and regulatory meetings. The vaccine technology focuses on immunizing against proteins linked to ovarian cancer, with the goal of significantly reducing its global impact. Anixa's partnership with the Cleveland Clinic enhances their capabilities in tackling cancer.

On May 20, 2021, Anixa Biosciences (NASDAQ: ANIX) announced that the U.S. FDA has detailed additional information needed for its Chimeric Antigen Receptor-T cell therapy (CAR-T) IND application, submitted in March in partnership with Moffitt Cancer Center. Anixa aims to provide the requested data within 30 days, with the FDA expected to respond in another 30 days. The CAR-T therapy targets the follicle stimulating hormone receptor, marking a novel approach in cancer treatment. Anixa is also pursuing vaccine programs for specific cancers like breast and ovarian cancer.

OntoChem GmbH has transferred its drug discovery technologies and collaborative assets with Anixa Biosciences, Inc. (NASDAQ: ANIX) to the newly established MolGenie GmbH. This transition focuses on developing an orally administered anti-viral treatment for Covid-19, leveraging data from recent studies. Anixa will collaborate with MolGenie to advance the project towards pre-clinical development, solidifying its commitment to combatting Covid-19. Leadership from both companies expresses optimism about the progress and future directions of this important partnership.

Anixa Biosciences, Inc. (NASDAQ: ANIX) announced that the FDA has requested additional information regarding its CAR-T therapy, developed in partnership with Moffitt Cancer Center. This therapy, which targets the follicle stimulating hormone receptor (FSHR), is currently on clinical hold under the IND application until further details are provided by the FDA. Anixa expects MCC to submit the requested information promptly. The therapy is part of Anixa's broader oncology programs aimed at advancing innovative treatments for cancer.

Anixa Biosciences (NASDAQ: ANIX) announced progression to the next stage of its anti-viral therapy against Covid-19 following successful Proof of Concept (POC) animal studies. The studies evaluated two compounds alongside Remdesivir in Syrian Hamsters, showing no adverse effects and comparable efficacy. Anixa aims to optimize pharmacokinetics and potency of a chosen compound over the next four to five months. The company is also developing therapies for cancer and infectious diseases, including innovative vaccine technologies.

Anixa Biosciences, Inc. (NASDAQ: ANIX) has announced an increase in its public offering of common stock, now totaling 4,285,715 shares at a price of $5.25 per share. This offering, set to close around March 25, 2021, could generate approximately $22.5 million in gross proceeds. The underwriter, H.C. Wainwright & Co., has an option for an additional 642,857 shares. Proceeds will support ongoing research, clinical trials, and potential acquisitions aligned with Anixa’s biotechnology focus on cancer and infectious diseases.

Anixa Biosciences, Inc. (NASDAQ: ANIX) has announced a public offering of 1,904,762 shares at $5.25 per share, with expected gross proceeds of approximately $10 million. The offering is led by H.C. Wainwright & Co. and aims to fund ongoing research, clinical trials, and the development of new technologies. The offering's closing is anticipated around March 25, 2021, pending customary conditions. The registration of shares was effective as of June 21, 2019, and further details will be filed with the SEC.

Anixa Biosciences (NASDAQ: ANIX) has filed an IND application for its ovarian cancer CAR-T therapy with the U.S. FDA as of March 22, 2021. This therapy, developed under the leadership of Dr. Jose Conejo-Garcia, targets the follicle stimulating hormone receptor (FSHR), offering hope to women with recurrent ovarian cancer, a group with limited treatment options. The company holds an exclusive commercial license for this technology, with clinical trials to be conducted at Moffitt Cancer Center. Successful FDA clearance could initiate their second therapy in clinical trials.